Riskpilot← Back to searchSign inGet full accessGeneBygg AB
ABActiveOrg 5591381701Frillesås Blåklintsväg 8Construction of residential and non-residential buildings · NACE 4100Est. 201712 employees
Revenue 2024
SEK 23,8M
+28% vs 2023
EBITDA margin
-2.9%
-183% vs 2023
Equity ratio
24.2%
Financial strength
Net profit 2024
SEK -89K
-135% vs 2023
| Revenue | SEK 23,8M | +28% |
| EBITDA | SEK -687K | -183% |
| Net profit | SEK -89K | -135% |
| Total assets | SEK 7,2M | -11% |
| Equity | SEK 1,8M | -5% |
| Employees | 12 | — |
Legal name
GeneBygg AB
Org number
5591381701
Legal form
Aktiebolag
NACE code
4100 · Construction of residential and non-residential buildings
Founded
7 december 2017
Share capital
SEK 50 000
Employees
12 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget ska bedriva byggnadsverksamhet. Ny till och ombyggnad av bostäder och lokaler. Handel med byggnadsvaror, samt därmed förenlig verksamhet.
Address
Frillesås Blåklintsväg 8
Email
info@genebygg.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 8 748 | 12 376 | 15 471 | 18 658 | 23 831 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 426 | 1 059 | 1 680 | 827 | −687 |
| Depreciation & amort. | −157 | −281 | −90 | −152 | −290 |
| EBIT | 269 | 778 | 1 590 | 675 | −977 |
| Net financials | −23 | −34 | −50 | −103 | −112 |
| Profit before tax | 246 | 614 | 600 | 332 | −89 |
| Tax | −57 | −128 | −130 | −77 | −0 |
| Net profit | 189 | 486 | 470 | 255 | −89 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 427 | 4 587 | 7 167 | 8 124 | 7 235 |
| Equity | 831 | 1 317 | 1 787 | 1 842 | 1 753 |
| Long-term debt | 1 003 | 921 | 1 597 | 1 605 | 1 520 |
| Short-term debt | 1 594 | 2 220 | 2 713 | 3 367 | 3 652 |
| Total debt | 2 597 | 3 141 | 4 310 | 4 972 | 5 172 |
EBITDA margin
-2.9%
This company
15.8%
Market median
-118% vs market
20202024
Equity ratio
24.2%
This company
38.2%
Market median
-37% vs market
20202024
Return on equity
-5.1%
This company
18.4%
Market median
-128% vs market
20202024
Net profit margin
-0.4%
This company
8.1%
Market median
-105% vs market
20202024
Asset turnover
3.29×
This company
1.12×
Market median
+194% vs market
20202024
Debt / equity
3.13×
This company
0.62×
Market median
-405% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KS | Audit | 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2019 | |
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2019 | |
| Chairman | 2019 | |
| Former (1) | ||
| Deputy Board Member | 2019 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GeneBygg AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Stefan Andersson | Audit | 0 companies |
| Carl Mikael Magnus Karlsson | Board of Directors | 0 companies |
| Lena Susanne Karlsson | Deputy Board Member | 0 companies |
| Klaus Johan Willi Genetorp | Deputy Board Member | 0 companies |
| Isabella Sofia Hildebrand | Deputy Board Member | 0 companies |
| Robin Nils-Fredrik Genetorp | Chairman | 0 companies |